

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08191-014002	Application No. 09/909,460
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) 37 CFR § 1.8(b)		Applicant Lynn B. Lunsford et al.	
		Filing Date July 18, 2001	Group Art Unit 1632

**RECEIVED**

OCT 21 2002

TECH CENTER 1600/2900

**U.S. Patent Documents**


Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
B	AB	WO 94/04121	03/03/1994	PCT				
B	AC	WO 97/03702	02/06/1997	PCT				
	AD							

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
B	AE	Partidos et al., "Biodegradable Microparticles as a Delivery System for Measles Virus Cytotoxic T Cell Epitopes," MOLECULAR IMMUNOLOGY 33(6):485-491 (1996)
	AF	

Examiner Signature 	Date Considered 1/23/03
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

AH #8

Sheet 1 9


TECH CENTER 1600/2900

SEP 20 2002

RECEIVED

Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
08191-014002Application No.  
09/909,460Information Disclosure Statement  
by Applicant

(Use several sheets if necessary)

Applicant  
Lynn B. Lunsford et al.Filing Date  
July 18, 2001Group Art Unit  
1633

## U.S. Patent Documents

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
AV	AA	3,520,970	07/21/1970	Lehmann et al.	424	25	
	AB	3,523,906	08/11/1970	Vrancken et al.	252	316	
	AC	3,737,337	06/05/1973	Schnoring et al.	117	100	
	AD	3,775,537	11/27/1973	Lehmann et al.	424	21	
	AE	3,821,422	06/28/1974	Morse et al.	426	72	
	AF	3,835,221	09/10/1974	Fulberth et al.	424	20	
	AG	3,860,733	01/14/1975	Morse et al.	426	302	
	AH	3,943,063	03/09/1976	Morishita et al.	252	316	
	AI	3,954,959	05/04/1976	Pedersen	424	21	
	AJ	3,972,999	08/03/1976	Tsuk	424	78	
	AK	4,016,254	04/05/1977	Seager	424	33	
	AL	4,083,949	04/11/1978	Benedikt	424	19	
	AM	4,182,778	01/08/1980	Hall et al.	426	72	
	AN	4,262,090	04/14/1981	Colby, Jr. et al.	435	91	
	AO	4,293,539	10/06/1981	Ludwig et al.	424	19	
	AP	4,321,253	03/23/1982	Beatty	424	35	
	AQ	4,384,975	05/24/1983	Fong	427	213.36	
	AR	4,462,839	07/31/1984	McGinley et al.	106	198	
	AS	4,518,433	05/21/1985	McGinley et al.	106	180	
	AT	4,623,588	11/18/1986	Nuwayser et al.	428	402.24	
	AU	4,637,905	01/20/1987	Gardner	264	4.3	
	AV	4,741,872	05/03/1988	De Luca et al.	264	4.7	
	AW	4,818,542	04/04/1989	DeLuca et al.	424	491	
	AX	4,897,268	01/30/1990	Tice et al.	424	422	
	AY	5,075,109	12/24/1991	Tice et al.	424	88	
	AZ	5,084,553	01/28/1992	Hess et al.	528	361	
	AAA	5,100,669	03/31/1992	Hyon et al.	424	426	

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

TECH CENTER 1600/2900

RECEIVED

SEP 20 2002



Substitute Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark Office

Attorney's Docket No.  
08191-014002

Application No.  
09/909,460

**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

Applicant  
Lynn B. Lunsford et al.

Filing Date  
July 18, 2001

Group Art Unit  
1633

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
W	ABB	5,126,147	06/30/1992	Silvestri et al.	424	497	
	ACC	5,160,745	11/03/1992	DeLuca et al.	424	487	
	ADD	5,180,765	01/19/1993	Sinclair	524	306	
	AEE	5,279,708	01/18/1994	Wood et al.	159	48.1	
	AFF	5,279,833	01/18/1994	Rose	424	450	
	AGG	5,354,556	10/11/1994	Sparks et al.	424	419	
	AHH	5,366,733	11/22/1994	Brizzolara et al.	424	426	
	AII	5,407,609	04/18/1995	Tice et al.	264	46	
	AJJ	5,413,797	05/09/1995	Khan et al.	424	489	
	AKK	5,417,986	05/23/1995	Reid et al.	424	499	
	ALL	5,460,831	10/24/1995	Kossovsky et al.	424	493	
	AMM	5,531,925	07/02/1996	Landh et al.	252	299.01	
	ANN	5,552,155	09/03/1996	Bailey et al.	424	450	
	AOO	5,580,859	12/03/1996	Felgner et al.	514	44	
	APP	5,589,466	12/31/1996	Felgner et al.	514	44	
	AQQ	5,622,649	04/22/1997	Hunter et al.	252	309	
	ARR	5,622,657	04/22/1997	Takada et al.	264	4.32	
	ASS	5,639,473	06/17/1997	Grinstaff et al.	424	450	
	ATT	5,648,096	07/15/1997	Gander et al.	424	489	
	AUU	5,650,173	07/22/1997	Ramstack et al.	424	489	
	AVV	5,651,990	07/29/1997	Takada et al.	424	497	
	AWW	5,652,283	07/29/1997	Boeckh et al.	524	47	
	AXX	5,656,297	08/12/1997	Bernstein et al.	424	484	
	AYY	5,656,469	08/12/1997	Tresco et al.	435	182	
	AZZ	5,662,938	09/02/1997	Vert et al.	424	501	
	AAAA	5,665,383	09/09/1997	Grinstaff et al.	488	804	
	ABBB	5,690,954	11/25/1997	Illum	424	434	

Examiner Signature

*Dw*

Date Considered

1/23/03

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



TECH CENTER 1600/2900

SEP 20 2002

RECEIVED

Substitute Form PTO-1449  
(Rev. 11-2001)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
08191-014002Application No.  
09/909,460**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant  
Lynn B. Lunsford et al.Filing Date  
July 18, 2001Group Art Unit  
1633**U.S. Patent Documents**

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
AK	ACCC	5,700,486	12/23/1997	Canal et al.	424	501	
	ADDD	5,723,269	03/03/1998	Akagi et al.	424	497	
	AEEE	5,739,118	04/14/1998	Carrano et al.	514	44	
	AFFF	5,783,567	07/21/1998	Hedley et al.	514	44	
	AGGG	5,792,366	08/11/1998	Coville	210	734	
	AHHH	5,811,128	09/22/1998	Tice et al.	424	501	
	AIII	5,814,344	09/29/1998	Tice et al.	424	501	
	AJJJ	5,820,883	10/13/1998	Tice et al.	424	501	
	AKKK	5,853,752	12/29/1998	Unger et al.	424	450	
	ALLL	5,853,763	12/29/1998	Tice et al.	424	489	
	AMMM	5,879,712	03/09/1999	Bomberger et al.	424	489	
	ANNN	5,879,713	03/09/1999	Roth et al.	424	489	
	AOOO	5,879,920	03/09/1999	Dale et al.	435	187	
	APPP	5,919,408	07/06/1999	Muller et al.	264	5	
	AQQQ	5,889,110	03/30/1999	Hutchinson	525	54.1	
	ARRR	5,945,126	08/31/1999	Thanoo et al.	424	489	
	ASSS	5,962,428	10/05/1999	Carrano et al.	514	44	
	ATTT	5,965,434	10/12/1999	Wolff et al.	435	320.1	
	AUUU	6,013,284	01/11/2000	Samain et al.	424	490	
	AVVV	6,025,337	02/15/2000	Truong et al.	514	44	
	AWWW	6,096,331	08/01/2000	Desai et al.	424	422	
	AXXX	6,159,502	12/12/2000	Russell-Jones et al.	424	422	
	AYYY	6,248,270 B1	06/19/2001	Tani et al.	264	36.1	
	AZZZ	6,312,727 B1	11/06/2001	Schacht et al.	424	490	
	AAAAA	6,312,731	11/06/2001	Staas et al.	424	501	
	ABBBB	6,322,789 B1	11/27/2001	Vitiello et al.	424	189.1	

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Signature

Date Considered

1/23/03

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TECH CENTER 1600/2900

SEP 24 2002

RECEIVED

Substitute Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark Office

Attorney's Docket No.  
08191-014002

Application No.  
09/909,460

**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

Applicant  
Lynn B. Lunsford et al.

Filing Date  
July 18, 2001

Group Art Unit  
1633

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
<i>Dr</i>	ACCCC	0257915	03/02/1988	EPO				
	ADDDD	WO 88/01213	02/25/1998	PCT				
	AEEEE	WO 88/08300	11/03/1988	PCT				
	AFFFF	WO 90/11092	10/04/1990	PCT				
	AGGGG	WO 90/13361	11/15/1990	PCT				
	AHHHH	WO 91/11092	07/25/1991	PCT			Abs.	
	AIIII	WO 91/19487	12/26/1991	PCT				
	AJJJJ	WO 92/06666	04/30/1992	PCT			Abs.	
	AKKKK	WO 93/19183	09/30/1993	PCT				
	ALLLL	WO 94/04171	03/03/1994	PCT				
	AMMMM	WO 94/04260	03/03/1994	PCT			Abs.	
	ANNNN	WO 94/09898	05/11/1994	PCT			Abs.	
	AOOOO	WO 94/18954	09/01/1994	PCT				
	APPPP	WO 94/23699	10/27/1994	PCT				
	AQQQQ	WO 94/23738	10/27/1994	PCT				
	ARRRR	WO 94/28873	12/22/1994	PCT				
	ASSSS	WO 94/28874	12/22/1994	PCT				
	ATTTT	WO 95/03356	02/02/1995	PCT				
	AUUUU	WO 95/03357	02/02/1995	PCT				
	AVVVV	WO 95/05853	03/02/1995	PCT				
	AWWWW	WO 95/07072	03/16/1995	PCT			Abs.	
	AXXXX	WO 95/17167	06/29/1995	PCT			Abs.	
	AYYYY	WO 95/20660	08/03/1995	PCT				
	AZZZZ	WO 95/21250	08/10/1995	PCT				
	AAAAA	WO 95/21931	08/17/1995	PCT				
	ABBBB	WO 95/24929	09/21/1995	PCT				
	ACCCC	WO 95/31184	11/23/1995	PCT				
	ADDDD	WO 95/31187	11/23/1995	PCT				

Examiner Signature

*Dr*

Date Considered

11/23/03

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
08191-014002Application No.  
09/909,460**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

Applicant  
Lynn B. Lunsford et al.Filing Date  
July 18, 2001Group Art Unit  
1633**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
<i>Q</i>	AEEEEEE	WO 95/35097	12/28/1995	PCT				
	AFFFFF	WO 96/00295	01/04/1996	PCT				
	AGGGGG	WO 96/11671	04/25/1996	PCT				
	AHHHHH	WO 96/20698	07/11/1996	PCT				
	AIIIII	WO 96/29998	10/03/1996	PCT				
	AJJJJJ	WO 96/36317	11/21/1996	PCT				
	AKKKKK	WO 97/17063	05/15/1997	PCT				
	ALLLLL	WO 97/36578	10/09/1997	PCT				
	AMMMMM	WO 97/42940	11/20/1997	PCT				
	ANNNNN	WO 98/31346	23.07.1998	PCT				
	AOOOOO	WO 98/31398	07/23/1998	PCT				
	APPPPP	WO 98/35654	08/20/1998	PCT				
	AQQQQQ	WO 98/51279	11/19/1998	PCT				
	ARRRRR	WO 99/58112	11/18/1999	PCT				
	ASSSSS	WO 00/03660	27.01.2000	PCT				
	ATTTTT	0 027 662 A1	04/29/1981	EPO			Abs.	
	AUUUUU	122 036	10/17/1984	EPO				
	AVVVVV	0 127 713 B1	12/12/1984	EPO				
	AWWWWW	145 240	06/19/1985	EPO				
	AXXXXX	0 161 640 A2	11/21/1985	EPO				
	AYYYYY	0 179 023 B1	04/23/1986	EPO			Abs.	
	AZZZZZ	248 531	12/09/1987	EPO				
	AAAAAA	0 250 038 A2	12/23/1987	EPO				
	ABBBBB	0 258 749 A2	03/09/1988	EPO				
	ACCCCC	266 119	05/04/1988	EPO				
	ADDDDD	0 302 582 B2	02/08/1989	EPO				
	AEEEEEE	0 330 180 B2	08/30/1989	EPO				

Examiner Signature

*Dah*

Date Considered

*1/23/03*

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEP 20 2002

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08191-014002	Application No. 09/909,460
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Lynn B. Lunsford et al.	
		Filing Date July 18, 2001	Group Art Unit 1633





### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
Dr	AAAAAA	0 333 523 B1	09/20/1989	EPO				
	AGGGGG	0 334 062 A2	09/27/1989	EPO				
	AHHHHH	0 374 531 A2	06/27/1990	EPO				
	AIHHH	0 451 390 A1	10/16/1991	EPO				
	AJJJJJ	0 451 391 A1	10/16/1991	EPO				
	AKKKKK	467 389	01/22/1992	EPO				
	ALLLLL	0 471 036 B1	02/19/1992	EPO				
	MMMMM	0 475 178 A1	03/18/1992	EPO				
	ANNNNN	0 531 497 B1	03/17/1993	EPO				
	AOOOOO	635 261	01/25/1995	EPO				
	APPPPP	706 792	04/17/1996	EPO				
	AQQQQQ	0 737 750 A2	10/16/1996	EPO				
	ARRRRR	076211A1	12/03/1997	EPO				
	ASSSSS	2 185 979	08/05/1987	UK				
	ATTTTT	FR 2660556	11/10/1991	France				
	AUUUUU	GB 2,147,501	05/15/1985	United Kingdom				
	AVVVVV	CA 2,126,685	10/18/1993	Canada				

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
Dr	AWWWWWW	Alexakis, T. et al., "Microencapsulation of DNA With Alginate Microspheres and Crosslinked Chitosan Membranes for in Vivo Application," <i>Appl. Biochem. Biotech.</i> 50:93-106 (1995).
	AXXXXXX	Alonso, Maria J. et al. "Determinants of release rate of tetanus vaccine from polyester microspheres" <i>Pharmaceutical Research (New York)</i> 10(7):945-953, 1993.
	AYYYYYY	Alpar et al., "Potential of Particulate Carriers for the Mucosal Delivery of DNA Vaccines", <i>Biochemical Society Transactions</i> , 25:337S, 1997
	AZZZZZZ	Amagai et al., "Autoantibodies against a Novel Epithelial Cadherin in Pemphigus Vulgaris, a Disease of Cell, Adhesion," <i>Cell</i> , 67:869-877, 1991
	AAAAAAA	Anderson, "Human gene therapy," <i>Nature</i> 392:25-30, 1998
	ABBBBBB	Bodmeier et al., "The Preparation and Evaluation of Drug-Containing Poly(dl-lactide) Microspheres Formed by the Solvent Evaporation Method," <i>Pharmaceutical Research</i> , 4:465, 466, 471, 1987

Examiner Signature 	Date Considered 11/23/03
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08191-014002	Application No. 09/909,460
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Lynn B. Lunsford et al.	
		Filing Date July 18, 2001	Group Art Unit 1633

(37 CFR 1.98(b))

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
W	ACCCCCCC	Brown, "Genetechnologie für Einsteiger"
	ADDDDDDD	Chang, "Biodegradable Semipermeable Microcapsules Containing Enzymes, Hormones, Vaccines, and Other Biologicals," <u>Journal of Bioengineering</u> , 1, pp 25-32 (1976)
	AEEEEEEE	Chasin et al., "Biodegradable Polymers as Drug Delivery Systems," University of Washington Libraries, pp. 1-41
	AFFFFFFF	Chen et al., "Protective Immunity Induced... Encapsulated in Microparticles", <u>Journal of Virology</u> , Vol. 72, No. 7, July 1998, pp 5757-5761.
	AGGGGGGG	Cowsar et al., "Poly(lactide-co-glycolide) Microcapsules for Controlled Release of Steroids," <u>Methods in Enzymology</u> , 112, pp 101-117 (May 1985)
	AHHHHHHH	Crystal, "Transfer of Genes to Humans:...to Success", <u>Science</u> , Vol. 270, 20 October 1995, pp 404-410.
	AIIIIIII	Eldridge et al., "Biodegradable and Biocompatible... Toxin-Neutralizing Antibodies", <u>Infection and Immunity</u> , Vol. 59, No. 9 Sept. 1991 pp 2978-2986.
	AJJJJJJJ	Eldridge et al., "Controlled Vaccine... Microspheres Target The Peyer's Patches", <u>Journal of Controlled Release</u> , Vol. 11, Nos. 1-3, 1990, pp 205-214.
	AKKKKKKK	Eppstein and Longenecker, "Alternative Delivery... Proteins As Drugs", <u>CRC Critical Review in Therapeutic Drug Carrier Systems</u> , Vol. 5, Issue 2, pp 99-139 (1988).
	ALLLLLLL	Etlinger, "Carrier sequence selection - one key to successful vaccines", <u>Immunology Today</u> , Vol. 13, No. 2, 1992, pp 52-55.
	AMMMMMMM	Florence, "The Oral... Nor Usual", <u>Pharm. Res.</u> , Vol. 14, No. 3, 1997, pp 259-266.
	ANNNNNNN	Ghaderi, Raouf et al. "Effect of preparative parameters on the characteristics of poly (D, L-lactide-co-glycolide) microspheres made by the double emulsion method" <u>Int. J. Pharm.</u> 141(1,2):205-216, 1996.
	AOOOOOOO	Gref et al., "Biodegradable Long-Circulating Polymeric Nanospheres," <u>Science</u> , 263:1600-1603, 1994
	APPPPPPP	Gunzburg and Salmons, "Virus vector design in gene therapy", <u>Molecular Medicine Today</u> , pp 410-417, 1995.
	AQQQQQQQ	Heard et al., "HLA and autoimmune disease," <u>HLA and Disease</u> , pp. 123-151, 1994
	ARRRRRRR	Hedley, "Genetic Modulation of Antigen Presentation," <u>MHC Molecules: Expression, Assembly &amp; Function</u> , Ch. 17, pp. 281-294; Editors, Robert G. Urban and Roman M. Chiczy; published by R.G. Landes & Co., 1996
	ASSSSSSS	Jacobs et al., "High-Level Expression of... Protection Elicited in a Murine Model", <u>J. Virol.</u> , Vol. 66, No. 4, April 1992, pp 2086-2095.
	ATTTTTTT	Jacobs et al., "Protection elicited by ...non-structural glycoprotein NSI", <u>J. Gen. Virol.</u> , Vol. 75, Part 9, September 1994, pp 2399-2402.
	AUUUUUUU	Jepson et al., "Comparison of ... Targeting to Intestinal M Cells", <u>J. Drug Targeting</u> , Vol. 1, 1993, pp 245-249.
	AVVVVVVV	Jeyanthi et al., "Development of a Biodegradable...Peptide", <u>Pharm. Res.</u> , Vol. 8, No. 10, October 1991, PDD 7097..
	AWWWWWWW	Jones et al., "Oral Delivery of Micro-Encapsulated DNA Vaccines", <u>Dev Biol Stand. Basel</u> , Karger, Vol. 92, 1998, pp 149-155.
	AXXXXXXX	Jones et al., "Orally Administered...Respiratory Infection", <u>Infect. Immun.</u> , Vol. 64, No. 2, February 1996, pp 489-494.
✓	AYYYYYYY	Jones et al., "Poly (DL-lactide-co-glycolide)-Encapsulated plasmid DNA Elicits Systemic and Mucosal Antibody, Responses to Encoded Protein After Oral Administration," <u>Vaccine</u> , 15:814-817, 1997


Examiner Signature

Date Considered

11/23/03

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





RECEIVED

SEP 10 2002

TECH CHAS. J. 1000/2900

Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
08191-014002Application No.  
09/909,460**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))


Applicant  
Lynn B. Lunsford et al.Filing Date  
July 18, 2001Group Art Unit  
1633**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
W	AZZZZZZZ	Jones et al., "Poly(lactide-co-glycolide)...vaccine antigens", <u>J. Biotech.</u> , Vol. 44, Nos. 1-3, 26 January 1996, pp 29-36.
	AAAAAAAAA	Jones et al., "Protection of mice...pertussis fimbriae", <u>Vaccine</u> , Vol. 13, No. 7, 1995, pp 675-681.
	ABBBBBBBB	Kreuter, "Nanoparticles...vaccine delivery", <u>J. Anat.</u> , Vol. 189, Part 3, December 1996, pp 503-505.
	ACCCCCCCC	Ledley, "Nonviral Gene Therapy: The Promise of Genes as Pharmaceutical Products", <u>Human Gene Therapy</u> , Vol. 6, No. 9, pp. 1129-1144, (September 1995).
	ADDDDDDDD	Lewis et al., "Biodegradable...antisense oligonucleotides", <u>J. Controlled Release</u> , Vol. 37, No. 1-2, November 1995, pp 173-183.
	AEEEEEEEE	McCluskie et al., "Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates," 5:287-300, 1999
	AFFFFFFFF	Miller et al., "Comet Assay...Ultrasonic Cavitation In Vitro", <u>Ultrasound in Med. &amp; Biol.</u> , Vol. 21, No. 6, pp-841-848 (1995).
	AGGGGGGGG	Morris, W. et al., "Potential of Polymer Microencapsulation ...Vaccine Innovation", <u>Vaccine</u> , Vol. 12, No. 1, pp 5-11 (1994).
	AHHHHHHHH	Murphy et al., "A novel MHC class II epitope expressed in thymic medulla but not cortex," <u>Nature</u> , 338:765-768, 1989
	AIIIIIII	Nakano et al., "Sustained Urinary Excretion of Sulfamethizole Following Oral Administration of Enteric, Coated Microcapsules in Humans," <u>International Journal of Pharmaceutics</u> , 4:291-298, 1980
	AJJJJJJJJ	Nellore et al., "Application of Biodegradable...Hepatitis B Surface Antigen Vaccination System", <u>Pharmaceutical Research</u> , Vol. 8, No. 10, pp S151, Abstract No. PDD 7098 (1991).
	AKKKKKKKK	Neutra et al., "Epithelial M Cells:...Immunization", <u>Cell</u> , Vol. 86, August 9, 1996, pp 345-348.
	ALLLLLLLL	Ngo et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," Birkhauser Boston, 14:492-495, 1994
	AMMMMMMMM	O'Hagan, "The intestinal uptake...antigen delivery", <u>J. Anat.</u> , Vol. 189, 1996, pp 477-482.
	ANNNNNNNN	Puyal et al., "A new cationic liposome...polynucleotides", Vol. 228, No. 3, March 1995, pp 697-703.
	AOOOOOOOO	Rajasubramanian et al., "Fabrication of Resorbable...Gene Therapy Applications", <u>ASAIO Journal</u> , Vol. 40, No. 3, pp 584-589 (July 1994).
	APPPPPPPP	Sah et al., "Biodegradable microcapsules prepared by...on their morphology and protein release", <u>Journal of Microencapsulation</u> , Vol. 12, No. 1, pp 59-69 (January 1995).
	AQQQQQQQQ	Shimoda et al., "HLA DRB4 0101-restricted Immunodominant T Cell Autoepitope of Pyruvate Dehydrogenase Complex, in Primary Biliary Cirrhosis: Evidence of Molecular Mimicry in Human Autoimmune Diseases," <u>J. Exp. Med.</u> , 181:1835-1845, 1995
	ARRRRRRRR	Spooner et al. "DNA vaccination for cancer treatment," <u>Gene Therapy</u> 2, pp 173-180 (1995)
	ASSSSSSSS	Steinman et al., "Escape from 'Horror Autotoxicus': Pathogenesis and Treatment of Autoimmune Disease," <u>Cell</u> , 80:7-10, 1995
	ATTTTTTTT	Tomlinson et al., "Controllable gene therapy Pharmaceutics of non-viral gene delivery systems," <u>Journal of Controlled Release</u> , 39:357-372, 1996
	AUUUUUUUU	Truong-Le, V.L. et al., "Gene Transfer by Gelatin-DNA Coacervate," <u>Proceed. Intern. Symp. Control. Rel. Bioact. Mater.</u> 22:466-467 (1995).
	AVVVVVVVV	Truong, V.L. et al., "Immuno-microsphere as Gene Delivery Vehicle: Targeting of LAMP-1 to Lysosomal Membrane," <u>Proceed. Intern. Symp. Control. Rel. Bioact. Mater.</u> 21:142-143 (1994).

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 9 of 9Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
08191-014002Application No.  
09/909,460**Information Disclosure Statement  
by Applicant**  
(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant  
Lynn B. Lunsford et al.Filing Date  
July 18, 2001Group Art Unit  
1633SEP 20 2002  
TECH CENTER 1600/2900

RECEIVED

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AWWWWWWW	Uchida et al., "Oral Delivery of Poly(lactide-co-glycolide) Microspheres Containing Ovlalbumin as a Vaccine Formulation: Particle Size Study," <u>Biol. Pharm. Bull.</u> 17(9) pp 1272-1276 (1994)
	AXXXXXXXXX	Urban et al., "The Discovery and Use of HLA-Associated Epitopes as Drugs", <u>Critical Reviews in Immunology</u> , 17:387-397, 1997
	AYYYYYYYY	Verma et al., "Gene therapy -- promises, problems and prospects," <u>Nature</u> , 389:239-42, 1997
	AZZZZZZZZ	Visscher et al., "Biodegradation of and tissue...microcapsules", <u>J. Biomed. Mater. Res.</u> , Vol. 19, No. 3, March 1985, pp 349-365.
	AAAAAAAAA	Wang et al., "Encapsulation of Plasmid DNA...Gene Delivery", <u>J8: Synthetic Non-Viral Gene Delivery Systems</u> , Keystone, CO, Abstract No. 120, January 19-25, 1998, p 132.
	ABBBBBBBB	Whalen, "DNA Vaccines for Emerging Infectious Diseases: What If?", <u>Emerging Infectious Diseases</u> , Vol. 2, No. 3, July-September 1996, pp 168-175.
	ACCCCCCCC	Wheeler et al., "Immunogenicity in Guinea Pigs and Tolerance in Grass Pollen-Sensitive Volunteers of Enteric-Coated Grass Pollen Allergens," <u>Int. Archs. Allergy appl. Immun.</u> 83, pp 354-358 (1987)
	ADDDDDDDD	Wolff et al., "Direct Gene Transfer into Mouse Muscle in Vivo," <u>Science</u> 247, 1465-1468 (1990)

Examiner Signature

Date Considered

11/23/03

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)